New University of Michigan Rogel Cancer Center results could provide peace of mind to certain breast, pancreatic, and colorectal cancer patients.
According to a release, germline genetic testing can help patients determine their cancer mortality risk. ATM, CHEK2 and PALB2 gene mutations do not increase a patient's risk of dying from the three cancers. “The risk of dying from breast, colorectal or pancreatic cancer was the same for patients with ATM, CHEK2 or PALB2 variants as for those without any genetic variant.”
The study is published in the Journal of Clinical Oncology.
